Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Cutaneous T-Cell Lymphoma
share announcement

Cutaneous T-Cell Lymphoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 7302

Special Issue Editor

Prof. Dr. Larisa J. Geskin

E-Mail Website
Guest Editor
Department of Dermatology, Columbia University, New York, NY 10032, USA
Interests: melanoma; immunotherapy; cutaneous T cell lymphoma (CTCL); dermatology; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cutaneous T-cell lymphoma (CTCL) is part of a diverse group of non-Hodgkin’s lymphomas characterized by the infiltration of malignant T lymphocytes expressing cutaneous lymphocyte antigen into the skin. Advances in histologic and molecular biologic techniques, including immunophenotyping and gene rearrangement studies, have expanded the capacity to diagnose CTCL, as well as provided for more precise subclassification of these entities. However, significant questions remain regarding the pathogenesis, classification, prognosis, and management of CTCL. Notably, there is presently no standard of care treatment for the most common variant of CTCL, mycosis fungoides (MF), or its leukemic variant, Sézary syndrome (SS). Together, these two forms of CTCL represent nearly 55% of all cases. While early-stage disease has an indolent course with a favorable prognosis, in advanced stages of disease prognosis is poor. Numerous therapeutic options are available, but none have been shown to improve survival, highlighting the importance of future clinical trials.

We invite experts in the field to contribute to this Special Issue addressing current and emerging data in the etiopathology, classification, prognosis, and therapeutic management of CTCL. The published articles will highlight recent developments in the understanding of CTCL, as well as critical, prospective research that will accelerate the field’s ability to subclassify and treat CTCL in the future. 

Prof. Dr. Larisa J. Geskin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Mycosis fungoides
  • Sézary syndrome
  • Cutaneous T-cell lymphoma
  • Skin cancer
  • Dermatologic oncology
  • Immunotherapy
  • Chemotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 907 KiB  
Article
Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study
by Marie Jouandet, Inès Nakouri, Lawrence Nadin, Alice Kieny, Mahtab Samimi, Henri Adamski, Gaëlle Quéreux, Guillaume Chaby, Anne Dompmartin and Jean-Matthieu L’Orphelin
Cancers 2022, 14(7), 1659; https://doi.org/10.3390/cancers14071659 - 25 Mar 2022
Cited by 9 | Viewed by 2586
Abstract
Background: Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are rare, aggressive cutaneous T-cell lymphomas that may be difficult to treat. Mogamulizumab is a recent monoclonal antibody targeting the CCR4 receptor expressed on the surface of Sézary cells. It can be prescribed in [...] Read more.
Background: Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are rare, aggressive cutaneous T-cell lymphomas that may be difficult to treat. Mogamulizumab is a recent monoclonal antibody targeting the CCR4 receptor expressed on the surface of Sézary cells. It can be prescribed in MF/SS stages III to IV in the second line after systemic therapy or in stages IB-II after two unsuccessful systemic therapies. We lack data on long-term efficiency and potential side effects in real-life conditions. Our study aims to determine efficacy considering the median PFS of advanced CTCL with mogamulizumab. Secondary objectives were to consider tolerance and estimate delay until side effects appeared. Methods: Data on patients with advanced cutaneous T-cell lymphomas were collected since French Authorization, in six French university hospitals. Patients were followed until they stopped mogamulizumab because of relapse or toxicity. For those still treated by mogamulizumab, the end point was 1 September 2021. We excluded 3 patients as they had already been included in the MAVORIC study and data was not available. Results: The median time of follow-up was 11.6 months. Of the 21 patients included, we reported four full-response patients, eight in partial response, one in stability, three in progression, and five were deceased. One patient had visceral progression, and seven had new lymphadenopathy. Progression-free survival was estimated at 22 months. Twenty patients presented adverse events, of which 10 were severe, i.e., grade III-IV. The median time between the introduction of mogamulizumab and the first adverse event was 21 days. Conclusions: Our study suggests that mogamulizumab can give patients with advanced refractory CTCL a consequent PFS, estimated at 22 months. The long-term safety of mogamulizumab was determined to be acceptable since we reported few grade III–IV AEs, comparable with other studies. No other study using real-life data has been performed to investigate the AEs of mogamulizumab. Full article
(This article belongs to the Special Issue Cutaneous T-Cell Lymphoma)
►▼ Show Figures

Figure 1

0 pages, 2289 KiB  
Article
JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL)
by Chella Krishna Vadivel, Maria Gluud, Sara Torres-Rusillo, Lasse Boding, Andreas Willerslev-Olsen, Terkild B. Buus, Tea Kirkegaard Nielsen, Jenny L. Persson, Charlotte M. Bonefeld, Carsten Geisler, Thorbjorn Krejsgaard, Anja T. Fuglsang, Niels Odum and Anders Woetmann
Cancers 2021, 13(2), 280; https://doi.org/10.3390/cancers13020280 - 14 Jan 2021
Cited by 19 | Viewed by 3915
Abstract
Perturbation in JAK-STAT signaling has been reported in the pathogenesis of cutaneous T cell lymphoma (CTCL). JAK3 is predominantly associated with the intra-cytoplasmic part of IL-2Rγc located in the plasma membrane of hematopoietic cells. Here we demonstrate that JAK3 is also ectopically expressed [...] Read more.
Perturbation in JAK-STAT signaling has been reported in the pathogenesis of cutaneous T cell lymphoma (CTCL). JAK3 is predominantly associated with the intra-cytoplasmic part of IL-2Rγc located in the plasma membrane of hematopoietic cells. Here we demonstrate that JAK3 is also ectopically expressed in the nucleus of malignant T cells. We detected nuclear JAK3 in various CTCL cell lines and primary malignant T cells from patients with Sézary syndrome, a leukemic variant of CTCL. Nuclear localization of JAK3 was independent of its kinase activity whereas STAT3 had a modest effect on nuclear JAK3 expression. Moreover, JAK3 nuclear localization was only weakly affected by blockage of nuclear export. An inhibitor of the nuclear export protein CRM1, Leptomycin B, induced an increased expression of SOCS3 in the nucleus, but only a weak increase in nuclear JAK3. Importantly, immunoprecipitation experiments indicated that JAK3 interacts with the nuclear protein POLR2A, the catalytic subunit of RNA Polymerase II. Kinase assays showed tyrosine phosphorylation of recombinant human Histone H3 by JAK3 in vitro—an effect which was blocked by the JAK inhibitor (Tofacitinib citrate). In conclusion, we provide the first evidence of nuclear localization of JAK3 in malignant T cells. Our findings suggest that JAK3 may have a cytokine-receptor independent function in the nucleus of malignant T cells, and thus a novel non-canonical role in CTCL. Full article
(This article belongs to the Special Issue Cutaneous T-Cell Lymphoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop